Name: SCH772984
Brand: Selleck Chemicals
SKU: S7101
Availability: InStock
Rating: 5 (563 reviews)

Jump to

Quality Control

Batch: Purity: 99.99%

99.99

Products Often Used Together with SCH772984

SB203580 (Adezmapimod)

LY294002 and this compound inhibit the VE-induced granulosa cell proliferation and promoted apoptosis, whereas the SB203580 had the opposite effects.

SP600125

It and SP600125 suppress the upregulated LAGE3-induced proliferation, migration, and invasion of Hep3B cells.

MG132

In HCT116 cells, this compound-induced downregulation of UHRF1 and DNMT1 proteins is not rescued by MG132.

Phenformin HCl

Phenformin enhances its antiproliferative activity in Mewo, M308, and SK-Mel-113 cells.

Related Targets	p38 MAPK Raf JNK MEK Ras KRas S6 Kinase MAP4K TAK1 Mixed Lineage Kinase
Other ERK Inhibitors	Ravoxertinib (GDC-0994) Ulixertinib (BVD-523) LY3214996 (Temuterkib) FR 180204 VX-11e XMD8-92 AZD0364 (ATG-017) ERK5-IN-1 Senkyunolide I MK-8353 (SCH900353)

Cell Culture, Treatment & Working Concentration

Cell Lines	Assay Type	Incubation Time	Activity Description	PMID
2P-ERK2	Growth Inhibition Assay		IC50=0.24 nM	25350931
A375	Function assay	2 hrs	Inhibition of ERK2 in human A375 cells harboring B-RAF V600E mutant assessed as decrease in phospho-ERK2 level after 2 hrs by Cellomics ArrayScanTM VTI imaging analysis, IC50 = 0.004 μM.	25977981
A375	Function assay		Inhibition of ERK2 in human A375 cells harboring BRAF V600E mutant assessed as decrease in phosphorylated ERK2 levels, IC50 = 0.004 μM.	28376306
COLO205	Antiproliferative assay	4 days	Antiproliferative activity against human COLO205 cells harboring BRAF V600E/D mutant measured after 4 days, IC50 = 0.016 μM.	30034615
A375	Function assay	2 hrs	Inhibition of ERK1/2 in human A375 cells harboring B-RAF V600E mutant assessed as decrease in phospho-RSK level after 2 hrs by Cellomics ArrayScanTM VTI imaging analysis, IC50 = 0.02 μM.	25977981
A375	Function assay	2 hrs	Inhibition of ERK1/2 in human A375 cells harboring B-RAF V600E mutant assessed as decrease in phospho-RSK level after 2 hrs by Cellomics ArrayScanTM VTI imaging analysis, IC50 = 0.02 μM.	25977981
A375	Function assay		Inhibition of ERK2 in human A375 cells harboring BRAF V600E mutant assessed as decrease in phosphorylated RSK levels, IC50 = 0.02 μM.	28376306
HT-29	Antiproliferative assay	4 days	Antiproliferative activity against human HT-29 cells harboring BRAF V600E/D mutant measured after 4 days, IC50 = 0.059 μM.	30034615
HT-29	Antiproliferative assay		Antiproliferative activity against human HT-29 cells harboring BRAF/KRAS mutant, IC50 = 0.059 μM.	29748051
A375	Antiproliferative assay	72 hrs	Antiproliferative activity against human A375 cells harboring B-RAF V600E mutant after 72 hrs by Cellomics ArrayScanTM VTI imaging analysis, IC50 = 0.07 μM.	25977981
HT-29	Apoptosis assay		Induction of apoptosis in human HT-29 cells harboring BRAF/KRAS mutant by caspase activation assay, IC50 = 0.096 μM.	29748051
Click to View More Cell Line Experimental Data

Solubility

In vitro
Batch:

DMSO : 14 mg/mL (23.82 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

DMSO : 25 mg/mL (42.54 mM) Warmed with 50°C water bath; Ultrasonicated;
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	10% DMSO 1 40% PEG 300 2 5%Tween80 3 45%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.600mg/ml (1.02mM)	Taking the 1 mL working solution as an example, add 100 μL of 6 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 450 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG 300 2 5%Tween80 3 ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.500mg/ml (0.85mM)	Taking the 1 mL working solution as an example, add 50 μL of 10 mg/ml clarified DMSO stock solution to 400 μL PEG300, mix evenly to clarify it; add 50 μL Tween80 to the above system, mix evenly to clarify it; then continue to add 500 μL ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

%

% Tween 80

% ddH₂O

% DMSO

+

%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	587.67	Formula	C₃₃H₃₃N₉O₂	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	942183-80-4	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	N/A			Smiles	C1CN(CC1C(=O)NC2=CC3=C(C=C2)NN=C3C4=CC=NC=C4)CC(=O)N5CCN(CC5)C6=CC=C(C=C6)C7=NC=CC=N7

Mechanism of Action

Features	Does not directly inhibit MEK1, MEK2, BRAF, or CRAF enzyme activity.
Targets/IC₅₀/Ki	ERK2 (Cell-free assay) 1 nM ERK1 (Cell-free assay) 4 nM
In vitro	SCH772984 is a novel, selective and ATP competitive inhibitor of ERK1/2. This compound inhibits phosphorylation of the ERK substrate p90 ribosomal S6 kinase (T359/S363 phospho-RSK) in a dose-dependent manner. It also inhibits phosphorylation of residues in the activation loop of ERK itself. This inhibitor demonstrates EC50 values <500 nM in approximately 88% and 49% of BRAF-mutant or RAS-mutant tumor lines, respectively. Importantly, it effectively inhibited MAPK signaling and cell proliferation in tumor cells resistant to concurrent treatment with BRAF and MEK inhibitors.
Kinase Assay	ERK2 IMAP enzymatic assay
Kinase Assay	SCH772984 is tested in 8 point dilution curves in duplicate against purified ERK2 or ERK1. The enzyme is added to the reaction plate. and incubated with this compound before adding a solution of substrate peptide and ATP. 14μl of diluted enzyme (0.3ng active ERK2 per reaction) is added to each well of a 384-well plate. The plates are gently shaken to mix the reagents and incubated for 45 minutes at room temperature. The reaction is stopped with 60μl of IMAP Binding Solution (1:2200 dilutions of IMAP beads in 1X Binding Buffer). The plates are incubated at room temperature for an additional 0.5 hours to allow complete binding of phosphopeptides to the IMAP beads. Plates are read on the LJL Analyst.
In vivo	SCH772984 induces tumor regressions in xenograft models at tolerated doses. This compound effectively inhibites MAPK signaling and cell proliferation in BRAF or MEK inhibitor resistant models.
References	[1] https://pubmed.ncbi.nlm.nih.gov/23614898/

Applications

Methods	Biomarkers	PMID
Western blot	cyclin B1 / cyclin D1 / p21 pRSK / pERK / pAKT / pMEK DUSP1 / DUSP4 / DUSP6 pCRAF(S338, S289, S296, S301) Aurora B / ETS1 / ETS2	26725216
Growth inhibition assay	Cell viability	30118499
Immunofluorescence	TOMM20 pERK1/2	30833752

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I would like to inhibit Erk1/2 by treating the mice with it. By what kind of administration way and at what concentration could this compound be used?

Answer:
It can be administered by I.P. The dosages can be used as: 12.5 mg/kg, 25 mg/kg, 50 mg/kg. For more detailed information please find the paper below: http://cancerdiscovery.aacrjournals.org/content/3/7/742.full

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

SCH772984 ERK1/2 inhibitor

Chemical Structure

Molecular Weight: 587.67